Etoposide, folinic acid, and 5-fluorouracil in carboplatin-pretreated patients with advanced gastric cancer

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF00686342PMID 1742854
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High dose folinic acid/etoposide/5-fluorouracil in advanced gastric cancer — a phase II study in elderly patients or patients with cardiac risk

  1990cited by this paper
• Phase II study of carboplatin in untreated inoperable advanced stomach cancer.

  1990cited by this paper
• New developments in the treatment of gastric carcinoma.

  1990cited by this paper
• Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer.

  1989cited by this paper
• Reporting results of cancer treatment

  1981cited by this paper

• Chapter 47 – Gastric/GE Junction Cancer

  2016cites this paper
• Gastric/GE Junction Cancer

  2012cites this paper
• Postoperative Chemotherapy in Resected Gastric Cancer: Results of a Single Center Experience

  2008cites this paper
• Phase II Study of Docetaxel and S-1Combination Therapy for Advanced or Recurrent Gastric Cancer

  2006cites this paper
• Phase II Study of Docetaxel and S-1 Combination Therapy for Advanced or Recurrent Gastric Cancer

  2006cites this paper
• Medical and Surgical Therapy for Gastric Cancer

  2006cites this paper
• Perspectives of surgery and multimodality treatment in gastric carcinoma

  2005influential citation
• Verso La Guarigione Dei Tumori Solidi “Early-Stage”: Ruolo Del Docetaxel

  2005cites this paper
• Review of second-line chemotherapy for advanced gastric adenocarcinoma.

  2005cites this paper
• Etoposide, leucovorin, 5-fluorouracil and interferon alpha-2b in elderly gastric cancer patients: a pilot study

  2004cites this paper
• Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer?

  2004cites this paper
• Curative treatment of gastric cancer: towards a multidisciplinary approach?

  2003cites this paper
• Chemotherapy in gastric cancer: a never ending saga.

  2003cites this paper
• Weekly treatment with irinotecan, folinic acid and infusional 5-fluorouracil (ILF) in patients with advanced gastric cancer

  2003cites this paper
• Treatment of advanced gastric cancer with etoposide, folinic acid, and fluorouracil in the clinical setting

  2002cites this paper
• Alternative methods of interpreting quality of life data in advanced gastrointestinal cancer patients

  2001cites this paper
• Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of

  2000cites this paper
• Phase II Study of Combined Administration of 5-Fluorouracil, Epirubicin and Mitomycin-C by Hepatic Artery Infusion in Patients with Liver Metastases of Gastric Cancer

  1999cites this paper
• Evaluation of clinical benefit of chemotherapy in patients with upper gastrointestinal cancer.

  1998cites this paper
• Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer.

  1998cites this paper
• Monitoring palliative chemotherapy in advanced gastrointestinal cancer using serial tissue polypeptide specific antigen (TPS) measurements.

  1996cites this paper
• Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer.

  1996cites this paper
• Phase II study of the etoposide, leucovorin and fluorouracil combination for patients with advanced gastric cancer unsuitable for aggressive chemotherapy.

  1995cites this paper
• Chemotherapy of gastric cancer

  1988cites this paper